The American company Pfizer announced that it will soon be able to supply the world with the vaccine doses it promised to deliver.
Pfizer had announced earlier that it was working on delivering two billion doses of vaccines against the emerging corona virus. (Covid-19) during the current year, before returning and announcing that the schedules of vaccine shipments were disturbed in the near term, and that shipments of the vaccine delivery that it developed will be affected between the end of January and the beginning of February.
However, she confirmed that it will provide a significant increase in doses to patients between February and March.
Pfizer will be able to supply the US with 200 million doses of the Covid-19 vaccine by the end of May, two months earlier than previously expected, according to its chief executive.
It was CEO Albert Burla said last Tuesday that the drug company and its partner, BioNTech, will be able to deliver the doses to the United States before the July 31 deadline.
The number of doses is six per bottle. It takes effect on Monday and applies to future supply contracts, according to a Pfizer representative.
In the US, Pfizer and BioNTech will deliver 120 million doses in the first quarter, 20 million more than they initially promised According to Burla, in an interview with Bloomberg.
This comes after the European Union Medicines Agency confirmed today, Friday, that the Pfizer / Biontech vaccine is not related to the deaths recorded among people who have received it and that it does not cause effects A new side, based on the first data related to its launch.
The agency said that it had seen the deaths that were recorded, including those that occurred among a number of elderly people, and “concluded that the data does not show a relationship to the order to receive the Pfizer vaccine. The cases do not raise any safety concerns. ”
Yesterday, Pfizer and Biontech announced that their vaccine against the“ Covid-19 ”epidemic preserves the bulk of its effectiveness against the two major mutations of the emerging corona virus in Britain and South Africa.
The statement said that laboratory tests “do not indicate the need for a new vaccine to deal with emerging variants.”